Evidence map›Paper›PMID 42367853›Full record

ArticlebioRxiv : the preprint server for biology2026

Azacytidine restores T cell function in AML by modulating DNA methylation.

Ravina Pandita, Yoko Kosaka, Jessica S Mulkey, Cora E Layman, Brett A Davis, Lucia Carbone, Evan F Lind

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ravina PanditaGraduate Program in Biomedical Sciences, Oregon Health & Science University, Portland Oregon, USA.ORCID 0000-0001-6110-6608
Yoko KosakaDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland Oregon, USA.
Jessica S MulkeyDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland Oregon, USA.
Cora E LaymanKnight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Brett A DavisKnight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0001-7985-1921
Lucia CarboneKnight Cancer Institute, Oregon Health & Science University, Portland Oregon, USA.
Evan F LindDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland Oregon, USA.ORCID 0000-0001-7026-2012

Funding

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Tothu Q Vu · 2017 to 2026
$13.9M
Pathways of Immune Evasion in Acute Myeloid LeukemiaR01CA262145 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Evan Ferguson Lind · 2022 to 2026
$1.7M
NCI NIH HHS R01 CA262145NCI NIH HHS U54 CA224019
6 · The paper itself

Abstract

AML is an aggressive blood cancer associated with poor clinical outcomes. Chemotherapy remains the standard of treatment, but unfortunately relapse is very common, highlighting the need for alternative therapies. T cell dysfunction and exhaustion are prominent in AML and may represent a barrier to effective immunotherapy yet remains poorly studied in AML. DNA methylation is a major driver of T cell exhaustion and inhibition of

Identifiers

PMID42367853
PMCPMC13308147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.